These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 1370538)
1. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538 [TBL] [Abstract][Full Text] [Related]
2. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200 [TBL] [Abstract][Full Text] [Related]
3. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. Megens AA; Niemegeers CJ; Awouters FH J Pharmacol Exp Ther; 1992 Jan; 260(1):160-7. PubMed ID: 1370539 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084 [TBL] [Abstract][Full Text] [Related]
5. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine. Awouters F; Niemegeers CJ; Megens AA; Janssen PA J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623 [TBL] [Abstract][Full Text] [Related]
6. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone. Janssen PA; Awouters FH Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873 [TBL] [Abstract][Full Text] [Related]
7. Biochemical profile of risperidone, a new antipsychotic. Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616 [TBL] [Abstract][Full Text] [Related]
8. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395 [TBL] [Abstract][Full Text] [Related]
9. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515 [TBL] [Abstract][Full Text] [Related]
10. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone]. Niemegeers CJ; Awouters F; Janssen PA Encephale; 1990; 16(2):147-51. PubMed ID: 1693560 [TBL] [Abstract][Full Text] [Related]
12. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes. Czyrak A; Skuza G; Rogóz Z; Frankiewicz T; Maj J Arzneimittelforschung; 1994 Feb; 44(2):113-8. PubMed ID: 7511901 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841. Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723 [TBL] [Abstract][Full Text] [Related]
16. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537 [TBL] [Abstract][Full Text] [Related]
17. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Leysen JE; Janssen PM; Megens AA; Schotte A J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908 [TBL] [Abstract][Full Text] [Related]
18. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Schotte A; Janssen PF; Megens AA; Leysen JE Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574 [TBL] [Abstract][Full Text] [Related]
19. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series. Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM; Wauquier A Arzneimittelforschung; 1975 Aug; 25(8):1287-94. PubMed ID: 1242360 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Czyrak A; Jaros T; Moryl E; Maj J Pharmacopsychiatry; 1993 Mar; 26(2):53-8. PubMed ID: 7690975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]